发明名称 |
Chimeric neuregulins and method of making and use thereof |
摘要 |
Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. |
申请公布号 |
US8933034(B2) |
申请公布日期 |
2015.01.13 |
申请号 |
US201313865812 |
申请日期 |
2013.04.18 |
申请人 |
Brain-Gen Biotech |
发明人 |
Ford Byron D. |
分类号 |
C07K14/475;C07K14/48;C07K16/18;A61K38/18;A61K45/06;A61K38/49;A61K38/48 |
主分类号 |
C07K14/475 |
代理机构 |
Andrews Kurth LLP |
代理人 |
Wang Ping;Andrews Kurth LLP |
主权项 |
1. A method for ameliorating neuronal damage in a subject, comprising: administering to said subject an effective amount of a pharmaceutical composition comprising: a chimeric neuregulin polypeptide having an integrin domain that binds to an integrin and an ErbB3/B4 binding domain that binds to ErbB3 and/or ErbB4, said chimeric neuregulin polypeptide comprising: a neuregulin backbone derived from a native neuregulin polypeptide, said neuregulin backbone comprising an ErbB3/B4 binding domain; and a donor fragment comprising a polypeptide derived from another neuregulin that is different from said native neuregulin, said donor fragment comprising an integrin binding domain, wherein said chimeric neuregulin comprises a neuregulin consensus motif comprising six cysteine residues spread in a region spanning an integrin binding domain and an ErbB3/ErbB4 binding domain and wherein said integrin binding domain comprises two positively charged amino acids at the amino-end of the first cysteine in the neuregulin consensus sequence, wherein the chimeric neuregulin polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 22, 23, 24, 27 and 28, and a pharmaceutically acceptable carrier. |
地址 |
Duluth GA US |